PRAME Protein

Catalog No. ABIN1589783

Product Details

Target: PRAME (Preferentially Expressed Antigen in Melanoma (PRAME))

Protein Type: Recombinant

Origin: Human

Source: Escherichia coli (E. coli)

Sequence: MNPLETLSIT NCRLSEGDVM HLSQSPSVSQ LSVLSLSGVM LTDVSPEPLQ ALLERASATL QDLVFDECGI TDDQLLALLP SLSHCSQLTT LSFYGNSISI

Characteristics: Length (AA): 106

Purity: > 98 % by SDS-PAGE. Visualized by silver stain

Application Details

Application Notes: Positive control for WB.

Comment:

Cytokines & Growth Factors

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Human PRAME should be reconstituted in water to a concentration of 0.1 mg/mL. This solution can be diluted in water or other buffer solutions or stored at -20 °C

Buffer: 10 mM Tris, 25 mM NaP, pH 7.4

Storage: 0 °C

Storage Comment: The lyophilized human PRAME, though stable at room temperature, is best stored desiccated below 0 °C. Reconstituted human PRAME should be stored in working aliquots at -20 °C.

Target Details

Target: PRAME (Preferentially Expressed Antigen in Melanoma (PRAME))

Alternative Name: PRAME (PRAME Products)

Synonyms: PRAME Protein, CT130 Protein, MAPE Protein, OIP-4 Protein, OIP4 Protein, 4930534P07Rik Protein, preferentially expressed antigen in melanoma Protein, PRAME Protein, Prame Protein

Background: PRAME/MAPE/OIP4 is a germinal tissue-specific gene that is also expressed at high levels in haematological malignancies and solid tumors. The physiological functions of PRAME in normal and tumor cells are unknown, although a role in the regulation of retinoic acid signaling has been proposed. Sequence homology and structural predictions suggest that PRAME is related to the Leucine-rich repeat (LRR) family of proteins, which have diverse functions. PRAME, or „preferentially expressed antigen in melanoma”, was originally identified as a gene encoding a HLA-A24 restricted antigenic peptide presented to autologous tumor-specific cytotoxic T lymphocytes derived from a patient with melanoma. PRAME is synonymous with MAPE (melanoma antigen preferentially expressed in tumors) and OIP4 (OPA-interacting protein 4), and its expression profile defines it as a cancer-testis antigen. Cancer-testis antigens (CTAs) are encoded by non-mutated genes expressed at high levels in germinal tissues and tumors, but which are absent from or detected at low levels in other tissues. PRAME may be somewhat different to other cancer-testis antigens in that it shows some expression in normal tissues such as ovary, adrenal, placenta and endometrium. The C-terminus of human PRAME (amino acids 453-509) was also identified to bind Neisseria gonorrhoeae opacity factors, in this case the OPA-P protein. Thus PRAME is also known as OIP4 (OPA interacting protein), although the functional implications of the interaction are unknown.
Synonyms: Melanoma antigen preferentially expressed in tumors, Opa-interacting protein 4, MAPE, OIP4

Molecular Weight: 10.7 kDa

NCBI Accession: NM_006115, NP_006106

UniProt: P78395

Pathways: Retinoic Acid Receptor Signaling Pathway, Nuclear Hormone Receptor Binding